2. Search Result
Search Result
Results for "

AG120

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18767
    Ivosidenib
    10+ Cited Publications

    AG-120

    		 Isocitrate Dehydrogenase (IDH) Metabolic Disease Cancer
    Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .
    Ivosidenib
  • HY-18767A
    (R,S)-Ivosidenib
    1 Publications Verification

    (R,S)-AG-120

    		 Isocitrate Dehydrogenase (IDH) Cancer
    (R,S)-Ivosidenib ((R,S)-AG-120) is the less active enantiomer of Ivosidenib (AG-120) .
    (R,S)-Ivosidenib
  • HY-18767S2
    Ivosidenib-13C5

    AG-120-13C5

    		 Isotope-Labeled Compounds Isocitrate Dehydrogenase (IDH) Metabolic Disease Cancer
    Ivosidenib- 13C5 (AG-120- 13C5) is 13C labeled Ivosidenib. Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .
    Ivosidenib-13C5
  • HY-18767S3
    Ivosidenib-d5

    AG-120-d5

    		 Isotope-Labeled Compounds Metabolic Disease Cancer
    Ivosidenib-d5 (AG-120-d5) is deuterium labeled Ivosidenib. Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity .
    Ivosidenib-d5
  • HY-120181
    AGI-14100

    		Isocitrate Dehydrogenase (IDH) Cancer
    AGI-14100 is a metabolically stable and orally available mIDH1 inhibitor (IC50=6 nM). The pharmacochemical optimization of AGI-14100 is aimed at eliminating hPXR activation, resulting in the final drug candidate AG-120. AG-120 can be used in the study of cancers carrying IDH1 mutations. The discovery and development of AGI-14100 can be used for further studies of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors .
    AGI-14100

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: